TScan Therapeutics (TCRX) Change in Account Payables (2020 - 2025)
Historic Change in Account Payables for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $1.9 million.
- TScan Therapeutics' Change in Account Payables rose 8858.54% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 72135.14%. This contributed to the annual value of $2.0 million for FY2024, which is 393461.54% up from last year.
- Per TScan Therapeutics' latest filing, its Change in Account Payables stood at $1.9 million for Q3 2025, which was up 8858.54% from -$435000.0 recorded in Q2 2025.
- TScan Therapeutics' 5-year Change in Account Payables high stood at $1.9 million for Q3 2025, and its period low was -$2.5 million during Q4 2021.
- Over the past 5 years, TScan Therapeutics' median Change in Account Payables value was $408000.0 (recorded in 2022), while the average stood at $238736.8.
- Per our database at Business Quant, TScan Therapeutics' Change in Account Payables tumbled by 449642.86% in 2021 and then skyrocketed by 47545.79% in 2024.
- Quarter analysis of 5 years shows TScan Therapeutics' Change in Account Payables stood at -$2.5 million in 2021, then skyrocketed by 116.82% to $414000.0 in 2022, then tumbled by 254.83% to -$641000.0 in 2023, then soared by 253.35% to $983000.0 in 2024, then surged by 96.64% to $1.9 million in 2025.
- Its Change in Account Payables was $1.9 million in Q3 2025, compared to -$435000.0 in Q2 2025 and $558000.0 in Q1 2025.